Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy

Neil Mehta, Jennifer L. Dodge, Aparna Goel, John Paul Roberts, Ryutaro Hirose, Francis Y. Yao – 23 September 2013 – It has been shown that patients with hepatocellular carcinoma (HCC) meeting the United Network for Organ Sharing T2 (Milan) criteria have an advantage in comparison with patients without HCC under the current organ allocation system for liver transplantation (LT). We hypothesized that within the T2 HCC group, there is a subgroup with a low risk of wait‐list dropout that should not receive the same listing priority.

Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation

Henry C. Lin, Luis Alvarez, Greggy Laroche, Hector Melin‐Aldana, Kim Pfeifer, Kathleen Schwarz, Peter F. Whitington, Estella M. Alonso, Udeme D. Ekong – 23 September 2013 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate–binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end‐stage liver disease.

Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease

Michel Blé, Victoria Aguilera, Angel Rubín, María García‐Eliz, Carmen Vinaixa, Martín Prieto, Marina Berenguer – 23 September 2013 – Hepatitis C virus (HCV) is associated with renal complications. We aimed to determine whether a sustained virological response (SVR) was associated with improvements in renal function (RF) in liver transplant (LT) recipients treated for HCV. Changes in RF were compared 1, 3, and 5 years after therapy as a function of the stage of chronic kidney disease (CKD) before treatment (BT).

Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Subscribe to